恩替卡韦联合干扰素α-2α对乙型病毒性肝炎患者HBV-DNA转阴的影响  

Effect of Entecavir Combined with Interferonα-2αon HBV-DNA Negative in Patients with Viral Hepatitis B

作　　者：刘媛媛 LIU Yuan-yuan(Department of Infectious Diseases,Tai'an Hospital of Traditional Chinese Medicine,Tai'an,Shandong Province,271000 China)

机构地区：[1]泰安市中医医院感染性疾病科,山东泰安271000

出　　处：《系统医学》2020年第1期16-18,共3页Systems Medicine

摘　　要：目的探讨恩替卡韦联合干扰素对乙型病毒性肝炎患者HBV-DNA转阴的影响。方法选择收治乙肝患者50例,所有患者均于2018年1月—2019年5月在该院接受治疗,随机分为实验组(n=25)和常规组(n=25)。常规组接受恩替卡韦治疗,实验组接受恩替卡韦联合干扰素治疗,治疗后对比两组HBV-DNA转阴率、HBV-DNA转阴突破率、不良反应发生情况。结果治疗3个月、治疗6个月、治疗12个月实验组HBV-DNA分别为(5.3±1.1)×10^5拷贝/mL、(4.1±1.4)×10^5拷贝/mL、(2.9±1.2)×10^5拷贝/mL、显著低于常规组的(5.9±1.2)×10^5拷贝/mL、(5.2±1.5)×10^5拷贝/mL、(4.2±1.6)×10^5拷贝/mL(t=1.83,P=0.04;t=2.68,P=0.01;t=3.25,P=0.00)。治疗3个月、治疗6个月、治疗12个月实验组HBV-DNA转阴率分别为52.0%、72.0%、84.0%,均显著高于常规组的24.0%、40.0%、56.0%(χ^2=4.16,P=0.04;χ^2=5.19,P=0.02;χ^2=4.67,P=0.03)。治疗治疗12个月实验组HBV-DNA转阴率4.0%,显著低于常规组的32.0%(χ^2=6.64,P=0.01)。实验组不良反应发生率32.0%,与常规组的24.0%对比差异无统计学意义(χ^2=0.40,P=0.53)。结论针对乙肝患者应用恩替卡韦联合干扰素治疗,可明显提升患者免疫功能,抑制乙型肝炎病毒复制,且安全性较高,值得进行广泛推广。Objective To investigate the effect of entecavir combined with interferon on HBV-DNA negative in patients with viral hepatitis B.Methods A total of 50 patients with hepatitis B were enrolled.All patients were treated in our hospital from January 2018 to May 2019.They were randomLy divided into experimental group(n=25)and routine group(n=25).The routine group received entecavir treatment,the experimental group received entecavir plus interferon treatment,after treatment,the two groups were compared with HBV-DNA negative rate,HBV-DNA negative breakthrough rate,and adverse reactions.Results The HBV-DNA of the experimental group was(5.3±1.1)×10^5 copies/mL,(4.1±1.4)×10^5 copies/mL,(2.9±1.2)×10^5 copies/mL for 3 months,6 months of treatment and 12 months of treatment,significantly lower than the conventional group(5.9±1.2)×10^5 copies/mL,(5.2±1.5)×10^5 copies/mL,(4.2±1.6)×10^5 copies/mL(t=1.83,P=0.04;t=2.68,P=0.01;t=3.25,P=0.00).The HBV-DNA negative conversion rate of the experimental group was 52.0%,72.0%,and 84.0%,respectively,after treatment for 3 months,treatment for 6 months,and treatment for 12 months,which were significantly higher than the conventional group's 24.0%,40.0%,and 56.0%(χ^2=4.16,P=0.04;χ^2=5.19,P=0.02;χ^2=4.67,P=0.03).The 12-month treatment group had a HBV-DNA negative rate of 4.0%,which was significantly lower than that of the conventional group 32.0%(χ^2=6.64,P=0.01).The incidence of adverse reactions in the experimental group was 32.0%,which was not statistically significant compared with the 24.0%in the conventional group(χ^2=0.40,P=0.53).Conclusion The application of entecavir combined with interferon in patients with hepatitis B can significantly improve the immune function of patients and inhibit the replication of hepatitis B virus,and it is safe and worthy of widespread promotion.

关 键 词：恩替卡韦 干扰素 乙型病毒性肝炎 HBV-DNA转阴 不良反应 

分 类 号：R512.6[医药卫生—内科学]